Clinical Trials Directory

Trials / Unknown

UnknownNCT04600219

The Effect of Tyrosine Kinase Receptor Axl on Dialysis Prognosis in Chronic Hemodialysis Patients

The Effect of Tyrosine Kinase Receptor Axl on Dialysis Prognosis in Chronic Hemodialysis Patients: a Cohort Study

Status
Unknown
Phase
Study type
Observational
Enrollment
250 (estimated)
Sponsor
Ai Peng · Academic / Other
Sex
All
Age
18 Years – 65 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to evaluate whether tyrosine kinase receptor Axl affects the dialysis prognosis in chronic hemodialysis patients

Detailed description

It is reported that hemodialysis (HD) patients often develop chronic systemic inflammatoion, and increased inflammatory activity is associated with vascular access failure, cardiovascular disease and death in HD patients. The interaction of Axl and its ligand Gas6 plays an important role in modulating immune response, inhabiting toll-like receptor (TLR) signaling and suppressing inflammatory cytokines production. Thus, we want to investigate the relationship between tyrosine kinase receptor Axl and the dialysis prognosis in HD patients in three-years follow-up.

Conditions

Timeline

Start date
2018-01-01
Primary completion
2021-12-01
Completion
2021-12-01
First posted
2020-10-23
Last updated
2020-11-03

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT04600219. Inclusion in this directory is not an endorsement.

The Effect of Tyrosine Kinase Receptor Axl on Dialysis Prognosis in Chronic Hemodialysis Patients (NCT04600219) · Clinical Trials Directory